Compare BGLC & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGLC | BRTX |
|---|---|---|
| Founded | 2017 | 1997 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 3.1M |
| IPO Year | 2019 | 2015 |
| Metric | BGLC | BRTX |
|---|---|---|
| Price | $1.01 | $1.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.7K | ★ 35.8K |
| Earning Date | 11-13-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,424,911.00 | $81,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $383.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.88 | $0.14 |
| 52 Week High | $5.50 | $30.17 |
| Indicator | BGLC | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.04 | 38.23 |
| Support Level | N/A | $1.28 |
| Resistance Level | $1.39 | $2.93 |
| Average True Range (ATR) | 0.05 | 0.15 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 44.17 | 51.28 |
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.